Skip to search formSkip to main contentSkip to account menu

T 614

Known as: T-614 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
T-614 (also named as iguratimod), a novel antirheumatic drug, could attenuate joint inflammation and articular damage in… 
Highly Cited
2009
Highly Cited
2009
OBJECTIVE To assess the efficacy and safety of T-614 versus methotrexate (MTX) in patients with active rheumatoid arthritis (RA… 
2009
2009
Iguratimod is a small molecule compound with anti-inflammatory and immunomodulatory actions, which has been developed as a… 
Highly Cited
2008
Highly Cited
2008
IntroductionT-614 is a novel oral antirheumatic agent for the treatment of rheumatoid arthritis. Whether it has immunomodulatory… 
Highly Cited
2003
Highly Cited
2003
OBJECTIVE To clarify the pharmacological action of an anti-rheumatic agent T-614, we investigated its effects on immunoglobulin… 
Highly Cited
2002
Highly Cited
2002
Abstract. Objective: Compound T-614, a member of the methanesulfoanilide class of anti-inflammatory agents, shows potent anti… 
Highly Cited
2001
Highly Cited
2001
OBJECTIVE To investigate the mechanism of the immunosuppressive effect of T-614 [N-(3-formylamino-4-oxo-6-phenoxy-4H-chromen-7-yl… 
2000
2000
A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized starting… 
Highly Cited
1995
Highly Cited
1995
To elucidate the mechanism for the selective inhibition of prostaglandin E2 (PGE2) production in inflammatory tissue by T-614 (3… 
1992
1992
In vitro effects of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-on e (T-614), a novel antiinflammatory…